Ipsen (Pharmaceuticals) Overview

  • Year Founded
  • 1929

Year Founded

  • Status
  • Public

  • Employees
  • 5,358

Employees

  • Stock Symbol
  • IPN

Stock Symbol

  • Investments
  • 30

  • Share Price
  • $119.80
  • (As of Thursday Closing)

Ipsen (Pharmaceuticals) General Information

Description

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Contact Information

Website
www.ipsen.com
Formerly Known As
Beaufour Laboratories
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 65, Quai Georges Gorse
  • 92100 Boulogne Billancourt
  • France
+33 01
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
PAR
Corporate Office
  • 65, Quai Georges Gorse
  • 92100 Boulogne Billancourt
  • France
+33 01

Ipsen (Pharmaceuticals) Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ipsen (Pharmaceuticals) Stock Performance

As of 12-Jun-2025, Ipsen (Pharmaceuticals)’s stock price is $119.80. Its current market cap is $9.9B with 83M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$119.80 $118.14 $101.23 - $136.22 $9.9B 83M 87.2K $4.52

Ipsen (Pharmaceuticals) Financials Summary

As of 31-Dec-2024, Ipsen (Pharmaceuticals) has a trailing 12-month revenue of $3.87B.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 9,014,965 9,014,965 9,966,269 8,455,154
Revenue 3,867,962 3,867,962 3,577,774 3,318,754
EBITDA 914,157 914,157 1,210,842 982,221
Net Income 374,298 374,298 697,289 681,940
Total Assets 6,700,242 6,700,242 6,989,333 6,021,083
Total Debt 444,116 444,116 412,867 657,701
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ipsen (Pharmaceuticals) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ipsen (Pharmaceuticals)‘s full profile, request access.

Request a free trial

Ipsen (Pharmaceuticals) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three
Pharmaceuticals
Boulogne Billancourt, France
5,358 As of 2024

North Chicago, IL
 

Milan, Italy
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ipsen (Pharmaceuticals) Competitors (43)

One of Ipsen (Pharmaceuticals)’s 43 competitors is AbbVie, a Corporation company based in North Chicago, IL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AbbVie Corporation North Chicago, IL
Recordati Formerly PE-Backed Milan, Italy
GSK Corporation London, United Kingdom
Cipla Corporation Mumbai, India
Novartis Corporation Basel, Switzerland
You’re viewing 5 of 43 competitors. Get the full list »

Ipsen (Pharmaceuticals) Patents

Ipsen (Pharmaceuticals) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202404021-D0 Cell-based neurotoxin assay Pending 20-Mar-2024
GB-202320108-D0 Biosensor Pending 28-Dec-2023
GB-202318884-D0 Formulation Pending 11-Dec-2023
GB-202307439-D0 Treatment of a headache disorder with botylinum neurotoxin a Inactive 18-May-2023
AU-2023351434-A1 Clostridial neurotoxin for use in a treatment of bladder pain syndrome Pending 30-Sep-2022 A61K38/4893
To view Ipsen (Pharmaceuticals)’s complete patent history, request access »

Ipsen (Pharmaceuticals) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ipsen (Pharmaceuticals) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ipsen (Pharmaceuticals)‘s full profile, request access.

Request a free trial

Ipsen (Pharmaceuticals) Investments & Acquisitions (30)

Ipsen (Pharmaceuticals)’s most recent deal was a Corporate Asset Purchase with Foreseen Biotech (Rights to Develop, Manufacture and Commercialize FS001) for . The deal was made on 11-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Foreseen Biotech (Rights to Develop, Manufacture and Commercialize FS001) 11-Jul-2024 Corporate Asset Purchase Buildings and Property
Ariceum 18-Apr-2023 Early Stage VC Pharmaceuticals
Albireo 02-Mar-2023 Merger/Acquisition Biotechnology
Epizyme 12-Aug-2022 Merger/Acquisition Drug Discovery
Bakx 18-Nov-2021 Early Stage VC Drug Discovery
You’re viewing 5 of 30 investments and acquisitions. Get the full list »

Ipsen (Pharmaceuticals) ESG

Risk Overview

Risk Rating

Updated September, 21, 2024

22.76 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Pharmaceuticals

Subindustry

of 419

Rank

Percentile

To view Ipsen (Pharmaceuticals)’s complete esg history, request access »

Ipsen (Pharmaceuticals) Exits (8)

Ipsen (Pharmaceuticals)’s most recent exit was on 16-Feb-2017 from Rhythm Pharmaceuticals. The exit was categorized as with 7 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Rhythm Pharmaceuticals 16-Feb-2017 Completed
  • 7 buyers
Motus Therapeutics 13-Aug-2015 Completed
  • 8 buyers
Rhythm Pharmaceuticals 13-Aug-2015 Completed
  • 9 buyers
Rhythm Pharmaceuticals 29-Jul-2013 Completed
  • 7 buyers
Inserm Transfert 12-Jan-2012 Later Stage VC Completed
  • 8 buyers
You’re viewing 5 of 8 exits. Get the full list »

Ipsen (Pharmaceuticals) Affiliates

Subsidiaries (8)

Name Industry Location Year Founded
Syntaxin Abingdon, United Kingdom 2005
Ipsen Poland Warsaw, Poland 2005
Canbex Therapeutics London, United Kingdom 2005
Ipsen Biopharmaceuticals Basking Ridge, NJ 2000
Sterix Oxford, United Kingdom 1998
You’re viewing 5 of 8 affiliates. Get the full list.  »

Ipsen (Pharmaceuticals) FAQs

  • When was Ipsen (Pharmaceuticals) founded?

    Ipsen (Pharmaceuticals) was founded in 1929.

  • Where is Ipsen (Pharmaceuticals) headquartered?

    Ipsen (Pharmaceuticals) is headquartered in Boulogne Billancourt, France.

  • What is the size of Ipsen (Pharmaceuticals)?

    Ipsen (Pharmaceuticals) has 5,358 total employees.

  • What industry is Ipsen (Pharmaceuticals) in?

    Ipsen (Pharmaceuticals)’s primary industry is Pharmaceuticals.

  • Is Ipsen (Pharmaceuticals) a private or public company?

    Ipsen (Pharmaceuticals) is a Public company.

  • What is Ipsen (Pharmaceuticals)’s stock symbol?

    The ticker symbol for Ipsen (Pharmaceuticals) is IPN.

  • What is the current stock price of Ipsen (Pharmaceuticals)?

    As of 12-Jun-2025 the stock price of Ipsen (Pharmaceuticals) is $119.80.

  • What is the current market cap of Ipsen (Pharmaceuticals)?

    The current market capitalization of Ipsen (Pharmaceuticals) is $9.9B.

  • What is Ipsen (Pharmaceuticals)’s current revenue?

    The trailing twelve month revenue for Ipsen (Pharmaceuticals) is $3.87B.

  • Who are Ipsen (Pharmaceuticals)’s competitors?

    AbbVie, Recordati, GSK, Cipla, and Novartis are some of the 43 competitors of Ipsen (Pharmaceuticals).

  • What is Ipsen (Pharmaceuticals)’s annual earnings per share (EPS)?

    Ipsen (Pharmaceuticals)’s EPS for 12 months was $4.52.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »